tiprankstipranks
Hansoh Pharmaceutical’s Drugs Renewed in China List
Company Announcements

Hansoh Pharmaceutical’s Drugs Renewed in China List

Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.

Don't Miss Our Christmas Offers:

Hansoh Pharmaceutical Group has announced the renewal of four innovative drugs in China’s 2024 National Reimbursement Drug List, enhancing their accessibility and affordability. This development is set to bolster the company’s market presence, with the renewed drugs addressing critical conditions such as non-small cell lung cancer and chronic myelogenous leukemia. The inclusion of these drugs in the national list reflects Hansoh’s commitment to pioneering domestic pharmaceutical advancements.

For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App